Developing as a significant development in the struggle against obesity, this medication is generating considerable attention . This treatment combines the action of two known GLP-1 binding agonists, dulaglutide , and an new glucose-dependent peptide component. Early study data have demonstrated significant fat reduction in individuals with a high